Ebb TIDES As Takeda’s Dengue Contender Weaker At 18 Months
Lower DENV-3 Efficacy A Concern?
Executive Summary
Takeda's TAK-003 generally positive in new 18-month analysis, but efficacy falls versus 12 months and lowest effectiveness again seen against serotype 3.
You may also be interested in...
Two Cheers For Panacea, Will It Get Three?
Promising data from Phase I clinical trials of a dengue vaccine and a $24.3m award by UN agencies for its Easyfive-TT pentavalent vaccine bode well for Panacea Biotec, but are they enough to turn the company’s fortunes around?
Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
Post-IPO Zentalis Plows New Ground With China Oncology Venture
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports